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ABSTRACT
Stargardt disease (STGD1; MIM 248200) is the most
prevalent inherited macular dystrophy and is associated
with disease-causing sequence variants in the gene
ABCA4. Signiﬁcant advances have been made over the
last 10 years in our understanding of both the clinical
and molecular features of STGD1, and also the
underlying pathophysiology, which has culminated in
ongoing and planned human clinical trials of novel
therapies. The aims of this review are to describe the
detailed phenotypic and genotypic characteristics of the
disease, conventional and novel imaging ﬁndings,
current knowledge of animal models and pathogenesis,
and the multiple avenues of intervention being explored.
INTRODUCTION
Stargardt disease (STGD1; MIM 248200) is the
most common inherited macular dystrophy in both
adults and children with a prevalence of 1 in 8000–
10 000.1–7 STGD1 has an autosomal recessive mode
of inheritance associated with disease-causing muta-
tions in the ABCA4 gene.8–11 It is both clinically and
genetically highly heterogeneous.5–7 12–17
Patients present with bilateral central visual loss,
including dyschromatopsia and central scotomata,
with characteristic macular atrophy and yellow–
white ﬂecks at the level of the retinal pigment epi-
thelium (RPE) at the posterior pole.1 5 13 18 19
Onset is most commonly in childhood, with
the next peak being early adulthood, and least
frequently in later adulthood, with a better progno-
sis generally associated with a later
onset.2 3 5 7 13 15 16 19 There is slow progressive
loss of retinal function and structure over time;
however, there is marked variability both within
and between families, suggesting that other import-
ant factors inﬂuence phenotype, including genetic
modiﬁers and the environment.12 15 16 20 21
Although there are currently no proven treat-
ments, there are three main avenues of intervention
being explored, with human clinical trials of stem
cell therapy, gene replacement therapy and pharma-
cological approaches.5 22–25
Clinical characteristics
The characteristics of STGD1 vary widely due to
the marked phenotypic heterogeneity associated
with the large number (>900) of disease-causing
sequence variants identiﬁed in ABCA4.26 There are
various manifestations of the disease resulting in a
spectrum of clinical presentations, rates of progres-
sion, imaging, psychophysical and electrophysio-
logical ﬁndings, and variable prognosis.
STGD1 commonly presents as progressive bilate-
ral central vision loss, with onset most often in
childhood and a second peak incidence in early
adulthood.3 5 7 There is increasing evidence that
onset relates to the severity of the underlying
ABCA4 variants, with childhood-onset STGD1
being associated with more deleterious variants
(including nonsense variants) compared with
adult-onset or the later onset ‘foveal-sparing’ (FS)
STGD1 (more frequently, missense var-
iants).3 7 15 16 27 Initially, ophthalmoscopy can
reveal a normal fundus or mild retinal abnormali-
ties (including loss of foveal reﬂex or mild RPE dis-
turbance) with or without vision loss.5 16 The
diagnosis can thereby be delayed unless retinal
imaging with fundus autoﬂuorescence (FAF) or
spectral-domain optical coherence tomography
(SD-OCT) and/or electrophysiological assessment
(including pattern, full-ﬁeld and multifocal electro-
retinography) are undertaken.3 SD-OCTwill reveal
loss of normal architecture that begins at the
central macula with relative preservation of the per-
ipheral macula in the ﬁrst instance and reduced
central autoﬂuorescence surrounded by an
increased signal or a bull’s-eye maculopathy-like
appearance on FAF.13 28 29 It is important to note
that up to a third of children at presentation may
not have retinal ﬂecks on fundoscopy or FAF —
these develop over time associated with increasing
macular atrophy; another reason the diagnosis is
often delayed is if retinal ﬂecks are not present
(ﬁgure 1).15 In very early childhood-onset disease
with relatively preserved vision, symmetrical
yellowish white ﬁne dots at the central macula may
also be seen.30 31
Although STGD1 is typically diagnosed in child-
hood or early adulthood, a later age of onset has
increasingly been recognised. Late-onset STGD1
(‘FS-STGD1’) is a milder phenotype with a better
prognosis and associated with foveal
sparing.15 16 19 32 Patients with FS-STGD1
often have relatively preserved visual acuity and iso-
lated macular dysfunction (normal full-ﬁeld electro-
retinography (ERG)); yet still exhibit the wide
phenotypic variability that is characteristic of
ABCA4-associated retinopathy, including rate of
progression—with relative stability in some patients
and more rapid progression in others.15 16 19 Given
that visual acuity may be relatively preserved, static
automated perimetry is helpful in detecting and
monitoring the pericentral ring-shaped scotoma
that may impair reading ability in FS-STGD1.27
The mechanism(s) of foveal sparing is unknown;
however, given that STGD1 is typically charac-
terised by early foveal degeneration, this phenotype
illustrates the potential inﬂuence of genetic and
environmental factors on the mechanism of cell
death; with evidence that speciﬁc missense variants
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may be more frequently observed in FS-STGD1 than non-FS
phenotype.15 Individual foveal morphological factors such as
cone density and macular pigment levels may also play a role in
determining the FS phenotype.33 34
Electrophysiological assessment including multifocal, pattern
and full-ﬁeld electroretinography can be helpful in conﬁrming
the diagnosis of STGD1 and in providing better-informed
advice on prognosis. Lois et al17 established a classiﬁcation of
three phenotypic subtypes of functional loss based on electro-
physiological attributes. Group 1 is classiﬁed as a severe pattern
ERG abnormality (macular dysfunction) with normal full-ﬁeld
ERGs; Group 2 is additional generalised loss of cone function;
and Group 3 is additional generalised loss of both cone and rod
function.17 A longitudinal study, incorporating the cohort of
patients used in the aforementioned cross-sectional study to
establish ERG group classiﬁcations, has now demonstrated that
these groups have prognostic implications and that they do not
reﬂect stages of disease; with Group 1 being associated with the
best prognosis, Group 3 with the worst and Group 2 with an
intermediate variable prognosis.2 A total of 22% of patients
from Group 1 showed ERG group transition during follow-up,
with 11% progressing to Group 2 and 11% to Group 3.2
Forty-seven per cent of patients in Group 2 progressed to
Group 3.2 There was clinically signiﬁcant ERG deterioration in
54% of all subjects: 22% of Group 1, 65% of Group 2 and
100% of Group 3. Therefore, all patients with initial rod ERG
involvement demonstrated clinically signiﬁcant electrophysio-
logical deterioration; only 20% of patients with normal full-
ﬁeld ERGs showed clinically signiﬁcant progression.2 Such data
assist counselling by providing more accurate prognostic infor-
mation (arguably the most accurate of all inherited retinal dis-
eases) and are also relevant in the design, patient selection and
monitoring of potential therapeutic interventions.
Imaging and disease progression
Imaging techniques providing enhanced assessment of retinal
architecture have proven valuable in diagnosis, monitoring and
probing the pathogenesis of STGD1, and include FAF, SD-OCT
and adaptive optics scanning light ophthalmoscopy (AOSLO).
FAF imaging, by exploiting the autoﬂuorescent properties of
lipofuscin and related metabolites, affords assessment of RPE
lipofuscin distribution in vivo.35 36 FAF has superseded fundus
ﬂuorescein angiography (FFA) in the diagnosis of STGD1,
which was previously used to identify the ‘dark choroid’
observed in STGD1 due to blockage of underlying choroidal
ﬂuorescence by RPE-laden lipofuscin;7 though, not all patients
have a dark choroid.18 Given that STGD1 is characterised by
abnormal levels of lipofuscin, FAF imaging may identify fundus
changes (early atrophy/ﬂecks/dots) before they are clinically
evident on ophthalmoscopy.3 37 38 An abnormally reduced FAF
signal results from an absence or reduction in RPE lipofuscin
density and/or RPE/photoreceptor cell loss.39 40 In contrast, an
abnormally increased FAF signal derives from excessive lipofus-
cin accumulation.40 Characteristic patterns of FAF, with areas of
increased and decreased FAF, are observed in STGD1, and aid
both diagnosis and measurement of progression over
time.5 13 41 Quantiﬁed autoﬂuorescence (qAF) has now been
developed to indirectly measure RPE lipofuscin in vivo.42
Signiﬁcantly elevated levels of qAF have been detected in
STGD1 compared with healthy controls.42 A potential concern
of qAF and conventional FAF is the use of short-wavelength
light which may exacerbate the phototoxicity associated with
ABCA4-related disease.43 In response to this, Cideciyan et al44
have developed short-wavelength reduced-illuminance auto-
ﬂuorescence imaging that has been also implemented in the
largest multicentre longitudinal study about the progression of
atrophy secondary to STGD1.45
Several studies have retrospectively evaluated longitudinal
FAF changes and patterns in STGD1. The largest published
series to date (n=68) classiﬁed patients into three FAF subtypes
at baseline: type 1 had a localised low signal at the fovea sur-
rounded by a homogeneous background (n=19), type 2 had a
localised low signal at the macula surrounded by a heteroge-
neous background with numerous foci of abnormal signal
(n=41) and type 3 had multiple low-signal areas at the posterior
pole with a heterogeneous background (n=8).13 The areas of
reduced AF signal were measured, and the rate of atrophy
enlargement (RAE) was calculated, with the mean follow-up
interval being 9.1 years. The RAE (mm2/year) based upon base-
line AF subtypes was signiﬁcantly different: 0.06 in type 1, 0.67
in type 2 and 4.37 in type 3. There was a signiﬁcant association
between AF subtype and genotype, with a preponderance of
milder sequence variants (including missense) in type 1 and
more deleterious sequence variants (including nonsense) being
Figure 1 (A) Colour fundus photograph showing typical yellow–white retinal ﬂecks with macular atrophy. (B) Corresponding fundus
autoﬂuorescence image showing ﬂecks of both increased and decreased autoﬂuorescence and reduced central macular autoﬂuorescence surrounded
by an increased signal.
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identiﬁed in type 3.13 The observation that AF pattern at base-
line inﬂuences the enlargement of atrophy over time and has
genetic correlates assists in the provision of counselling on prog-
nosis in STGD1 and is valuable for clinical trials.
SD-OCT provides high-resolution cross-sectional images of
retinal lamination and allows early detection of foveal outer
retinal loss, which is the hallmark of childhood- and adulthood-
onset STGD1 (ﬁgure 2). The earliest OCT abnormality which
has been detected in children, as young as 5 years of age, is
external limiting membrane thickening, prior to the develop-
ment of atrophy.30 31 46 47 Serial OCT imaging may be
employed to monitor progression by measuring changes in
several parameters including total retinal thickness and macular
volume, outer retinal thickness, outer nuclear layer (ONL)
thickness and inner segment ellipsoid loss.28 For the purposes
of clinical trial end-point validation, the demonstration of struc-
ture–function correlation will also likely be necessary.5 It is
noteworthy that it has been shown that central foveal thickness
on OCT correlates with visual acuity loss.27
AOSLO allows in vivo cellular imaging, with custom-built
research systems now able to visualise rods, cones—including
foveal cones––and RPE mosaics (ﬁgure 2).48 Both confocal and
split-detector (SD; non-confocal) AOSLO imaging can be under-
taken.48 Confocal imaging requires relatively intact photo-
receptor outer segment structure to detect wave-guiding
photoreceptor cells. This thereby results in a signiﬁcant number
of ‘dark spaces’ observed in the cone mosaics of patients with
STGD1, where it was unknown until the advent of SD-AOSLO
whether these dark spaces lacked an optical signal due to lack of
cones or whether cones were present but not wave-
guiding.33 47 49 50 This has fundamental implications for deter-
mining participant suitability and selection for intervention, and
thereby clinical trial design and the likelihood of detecting
safety and efﬁcacy signals robustly and sensitively. In direct con-
trast, SD imaging does not require intact outer segments, but
affords imaging of inner segments. The dark spaces have now
been shown in many cases to harbour inner segments, although
often ‘swollen’ compared with normal cone inner segments,
suggesting there are more cones than previously imaged with
confocal techniques that could potentially be rescued with novel
therapies, including gene replacement. Moreover, SD imaging
has identiﬁed cones that would not have been predicted on the
basis of OCT alone, suggesting that AO imaging may be a more
sensitive measure of photoreceptor integrity.48–50 However,
these pilot observations need to be applied to large cohorts of
molecularly proven patients over time, including quantitative
AOSLO-derived measurements to determine disease progression
on a cellular level over time, including foveal and parafoveal
(‘transition zone’) cone densities and cone spacing.33 47 49
Structure–function correlations will also be valuable—with
abnormal cone spacing having been previously shown to correl-
ate to abnormal FAF and reduced visual function.47
The vast majority of data to date on disease progression is
retrospective from single centres and thereby inherently limited.
Figure 2 Multimodal imaging of the
right eye of a molecularly proven
15-year-old patient with Stargardt
disease. (A) Fundus autoﬂuorescence
image. The yellow line indicates the
scanning level of the optical coherence
tomography (OCT) scan in (B). (B) OCT
scan showing central loss of outer
retinal structure. The yellow arrows
indicate the location and extent of the
adaptive optics scanning light
ophthalmoscopy (AOSLO) montages in
(C) and (D) through the transition
zone. (C) Confocal AOSLO montage of
the photoreceptor mosaic.
(D) Split-detection AOSLO montage of
the photoreceptor mosaic. The far left
side of (C) and (D) is closer to the
fovea and lacks cone structure,
corresponding with the lack of outer
hyper-reﬂective layers in (B). Moving
towards the right of (C) and (D), away
from the fovea and superiorly on the
retina, (C) shows structural changes
that are relatively challenging to
interpret, whereas (D) clearly shows
the presence of cones. Scale bars
represent 100 mm.48
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There is a need for prospective natural history studies of large
cohorts of molecularly proven patients. One such ongoing mul-
ticentre international study is the ‘Progression of Atrophy
Secondary to Stargardt Disease (ProgStar)’ study that charac-
terises disease progression using psychophysical measures (such
as mesopic and scotopic microperimetry) and imaging (SD-OCT
and FAF) to establish endpoints for clinical trials of emerging
therapies.5
Molecular genetics
STGD1 is inherited in an autosomal recessive fashion and is
caused by sequence variants in the gene ABCA4, with the carrier
frequency believed to be up to 1 in 20.51 Disease-causing
variants in ABCA4 are also associated with cone dystrophy,
cone–rod and ‘rod–cone’ dystrophy. ABCA4 is a large, highly
polymorphic gene, consisting of 50 exons, with over 900
disease-associated variants reported to date.9 10 26 52–54 This
highly polymorphic nature and large number of variants make
ascribing deﬁnite disease-causation problematic; moreover, the
vast allelic heterogeneity makes genotype–phenotype correla-
tions very challenging indeed. In general, missense variants are
associated with milder, later onset disease, while null alleles are
associated with more severe, earlier onset disease; however,
certain missense variants can also have severe functional effects
similar to nulls (eg, p.Leu541Pro and p.Ala1038Val (complex),
and p.Arg1640Trp).14 55 56 The interaction between variants
may also affect the functional outcome; while there is evidence
that p.Gly1961Glu in the homozygous state typically causes a
milder phenotype, a more severe phenotype results when asso-
ciated with various additional ABCA4 mutations.14 57 Certain
missense variants appear to be more commonly observed in the
mildest ABCA4-associated phenotype, FS-STGD1, including
p.Arg2030Gln.15 58
ABCA4 is a member of the ABC transporter gene superfamily,
encoding the retinal speciﬁc transmembrane ABCA4 protein, a
member of the ATP-binding cassette transporter superfamily.59 60
ABCA4 is localised to the rim of the rod and cone outer
segment discs, and is involved in the active transport of reti-
noids from photoreceptor to RPE.59–61
The high allelic heterogeneity makes molecular genetic testing
of ABCA4-associated retinal disease very challenging. It has been
reported that direct Sanger sequencing of the entire ABCA4
coding region detects between 66% and 80% of disease-causing
alleles; however, this is not practically or economically possible
in large cohorts.58 62 Arrayed primer extension (APEX) tech-
nology, which screens for all known previously reported ABCA4
variants, detects approximately 65% to 75% of all
disease-associated alleles.63 64 However, by deﬁnition, novel var-
iants are not detected by APEX technology, necessitating the use
of other methodologies for high-throughput systematic screen-
ing of the entire coding region, especially in cases where one or
both disease-causing alleles have failed to be identiﬁed by the
array. A high-throughput strategy based on next-generation
sequencing has now been shown to be highly effective in detect-
ing both alleles, including new ABCA4 variants not included in
the APEX array.9 10 The identiﬁcation of both disease-causing
alleles improves the accuracy of diagnosis and the counselling of
patients, and also assists in more effective patient selection of
genetically conﬁrmed participants for current and future clinical
trials.
Pathogenesis and animal models
The visual cycle consists of enzyme-catalysed reactions convert-
ing all-trans retinal, derived from the photobleaching of
rhodopsin and cone opsin, back to 11-cis retinal.60 65 All-trans
retinal is released from the light-activated rhodopsin or cone
opsin into the rod and cone outer segments, respectively, and
forms a complex with phosphatidylethanolamine (PE) resulting
in N-retinylidene-phosphatidylethanolamine (N-ret-PE), which
is transported to the disc surface by ABCA4. The lack of, or
inefﬁcient removal of, N-ret-PE from photoreceptor outer seg-
ments, secondary to ABCA4 dysfunction/mislocalisation, results
in an accumulation of bisretinoid compounds in outer segment
discs, and ultimately in toxic levels of bisretinoid A2PE in
photoreceptor membranes.43 60 65 A2PE is hydrolysed to form
the highly toxic metabolite A2E, which accumulates as a compo-
nent of lipofuscin in RPE cells, and ultimately results in RPE
dysfunction and death, with subsequent photoreceptor dysfunc-
tion/loss.43 66 67 While the commonly accepted RPE failure fol-
lowed by subsequent photoreceptor cell dysfunction/death may
be the sequence of events in the majority of ABCA4-asociated
disease, it may not be the case in, for example, FS-STGD1.15
While the STGD1 mouse model (ABCA4 knockout) has sig-
niﬁcant limitations, including that mice lack a macula (the
primary area affected in STGD1) and the disease in mice is of
later onset and exhibits slower degeneration than that seen in
patients, it has helped shed light on the aforementioned under-
lying pathogenesis. Signiﬁcantly elevated retinal levels of A2E
and other lipofuscin ﬂuorophores have been identiﬁed in this
model.61 The ABCA4 knockout mice show delayed dark adapta-
tion, increased all-trans-retinaldehyde following light exposure,
increased PE in outer segments and accumulation of N-ret-PE.
Moreover, they have an accelerated deposition of lipofuscin and
A2E in the RPE, supporting ABCA4’s role as a transporter of
N-ret-PE across disc membranes.68 The ﬁnding that the retinal
degeneration in the knockout mouse was accelerated with
exposure to signiﬁcantly bright (ultraviolet) light69 70 and inges-
tion of large doses of vitamin A43 71 has led to patients with
STGD1 being advised to avoid excessive exposure to bright sun-
light and wear good-quality sunglasses with UVA/UVB blocking
properties, and to also avoid vitamin A supplementation.
Interestingly, in a light exposure study, ﬁve patients with STGD1
who wore a black contact lens in one eye during waking hours
for 12 months were observed to have less progression on FAF
imaging in their study eye compared with the fellow eye.72
Avenues of intervention
STGD1 is currently subject to more clinical trials than any other
inherited retinal disease, with gene replacement, stem cell
therapy and pharmacological approaches.
Gene replacement therapy targets viable photoreceptors, with
the underlying aim being to slow or prevent further retinal
degeneration; so, the earlier the intervention the better.
Adeno-associated virus (AAV) vectors have been the gene trans-
fer system of choice for human gene therapy, including retinal
diseases.73 74 However, a major limitation is that ABCA4 is
larger than the current AAV vector capacity, a challenge that
needs to be addressed for other genes that commonly cause
inherited retinal disease, including USH2A.75 Subretinal injec-
tion of a lentivirus vector delivering ABCA4 has therefore been
developed, given the larger cargo capacity of lentiviruses, and is
currently in an ongoing Phase I/II clinical trial (ClinicalTrials.
gov Identiﬁer: NCT01367444). There have been no safety con-
cerns in the ﬁrst three cohorts of subjects with relatively
advanced disease, and no deﬁnite evidence of efﬁcacy, with the
ﬁnal cohort with less severe disease now being recruited, with
arguably more potential to show beneﬁt.22 24 76
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In view of the fact that RPE cell dysfunction/loss is believed
to precede photoreceptor cell dysfunction/loss in STGD1 and
that RPE cells can be generated in the laboratory relatively
easily, a Phase I/II stem cell therapy trial (ClinicalTrials.gov
Identiﬁer: NCT01469832) has been undertaken using human
embryonic stem cell derived RPE cells transplanted subretinally
in patients with severe advanced STGD1.23 There have been no
safety concerns to date, and efﬁcacy data are awaited. It remains
possible that RPE cell replacement alone will be insufﬁcient and
that photoreceptor cells will need to also be transplanted.
There are many drugs that are already available or have been
speciﬁcally developed that target different aspects of the visual
cycle (vitamin A recycling pathway) and may thereby be poten-
tially beneﬁcial in slowing or stopping progression in STGD1.65
These include agents aimed at either (i) reducing the formation
of toxic by-products of the visual cycle, by reducing delivery of
vitamin A or inhibition of various enzymes participating in the
visual cycle, or (ii) directly targeting toxic metabolites such as
A2E. One of these drugs, which aims to allow normal visual
cycle function and yet stop N-ret-PE and A2E formation, is a
chemically modiﬁed vitamin A taken orally that will compete
with dietary vitamin A, normally enter the visual cycle, but will
not dimerise and therefore not exit the visual cycle to generate
A2E.25 77 78 This is currently being investigated in a Phase II
clinical trial (ClinicalTrials.gov Identiﬁer NCT02402660).
CONCLUSIONS
STGD1 is one of the most common causes of inherited child-
hood and adulthood visual impairment, with inherited retinal
disease now being the most common cause of certiﬁable blind-
ness in the working age population in England and Wales and
the second most common in childhood.79 STGD1 is both
phenotypically and genetically highly heterogeneous with sig-
niﬁcant advances having been made in our ability to identify the
disease at the earliest stages, characterise clinical features that
allow better-informed advice on prognosis, perform accurate
rapid molecular genetic testing, and in our understanding of
underlying disease mechanisms. These developments have
allowed multiple clinical trials to be currently ongoing
with many more, especially drug trials, anticipated over the next
5–10 years. Further robust longitudinal prospective natural
history studies, probing genotype–phenotype and structure–
function associations, are crucial in order to provide improved
prognostication and genetic counselling, as well as optimisation
of clinical trial design, including identifying suitable partici-
pants, windows of opportunity and the most sensitive and reli-
able outcome metrics.
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